Literature DB >> 15621843

Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.

G Visani, B Guiducci, F D'Adamo, A Mele, G Nicolini, G Leopardi, G Sparaventi, S Barulli, L Malerba, A Isidori, M Malagola, P P Piccaluga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15621843     DOI： 10.1080/10428190400013688

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.

Authors:  Mathilde Hunault-Berger; Thibaut Leguay; Xavier Thomas; Ollivier Legrand; Françoise Huguet; Caroline Bonmati; Martine Escoffre-Barbe; Laurence Legros; Pascal Turlure; Patrice Chevallier; Fabrice Larosa; Frederic Garban; Oumedaly Reman; Philippe Rousselot; Nathalie Dhédin; André Delannoy; Marina Lafage-Pochitaloff; Marie Christine Béné; Norbert Ifrah; Hervé Dombret
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas.

Authors:  Yun Fan; Neng-ming Lin; Lü-hong Luo; Luo Fang; Zhi-yu Huang; Hai-feng Yu; Feng-qin Wu
Journal:  Acta Pharmacol Sin       Date:  2011-03       Impact factor: 6.150

3.  Pegylated liposomal doxorubicin for myeloid neoplasms.

Authors:  Cheng Zhang; Han Yao; Pei-Yang Kong; Yao Liu; Lei Gao; Li Gao; Ying-Ying Ma; Jun Liu; Xu Tan; Xi Zhang
Journal:  Anticancer Drugs       Date:  2019-10       Impact factor: 2.248
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.